JP2024510975A5 - - Google Patents

Info

Publication number
JP2024510975A5
JP2024510975A5 JP2023555527A JP2023555527A JP2024510975A5 JP 2024510975 A5 JP2024510975 A5 JP 2024510975A5 JP 2023555527 A JP2023555527 A JP 2023555527A JP 2023555527 A JP2023555527 A JP 2023555527A JP 2024510975 A5 JP2024510975 A5 JP 2024510975A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
prostate cancer
approximately
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510975A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/019662 external-priority patent/WO2022192481A1/en
Publication of JP2024510975A publication Critical patent/JP2024510975A/ja
Publication of JP2024510975A5 publication Critical patent/JP2024510975A5/ja
Pending legal-status Critical Current

Links

JP2023555527A 2021-03-12 2022-03-10 前立腺癌を処置する方法 Pending JP2024510975A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163160319P 2021-03-12 2021-03-12
US63/160,319 2021-03-12
PCT/US2022/019662 WO2022192481A1 (en) 2021-03-12 2022-03-10 Methods of treating prostate cancer

Publications (2)

Publication Number Publication Date
JP2024510975A JP2024510975A (ja) 2024-03-12
JP2024510975A5 true JP2024510975A5 (cg-RX-API-DMAC7.html) 2025-03-18

Family

ID=80952117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555527A Pending JP2024510975A (ja) 2021-03-12 2022-03-10 前立腺癌を処置する方法

Country Status (7)

Country Link
US (1) US12016847B2 (cg-RX-API-DMAC7.html)
EP (1) EP4304589B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024510975A (cg-RX-API-DMAC7.html)
KR (1) KR20230156107A (cg-RX-API-DMAC7.html)
CN (1) CN117241797A (cg-RX-API-DMAC7.html)
ES (1) ES3076129T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022192481A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073923A1 (es) 2008-10-31 2010-12-09 Medivation Technologies Inc Pirido( 4,3-b) indoles que contienen restos rigidos
CN102257076B (zh) 2008-12-18 2014-07-30 纳幕尔杜邦公司 具有新颜料的粉末涂料组合物
US8580399B2 (en) 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
KR20140068883A (ko) 2011-09-28 2014-06-09 이데미쓰 고산 가부시키가이샤 유기 전계 발광 소자용 재료 및 이를 사용한 유기 전계 발광 소자
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2961747B1 (en) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
US9458156B2 (en) * 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EA201990240A1 (ru) * 2013-12-24 2019-06-28 Бристол-Маерс Сквибб Компани Новые трициклические соединения в качестве противораковых средств
US9580430B2 (en) * 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
RU2745999C1 (ru) * 2014-12-05 2021-04-05 Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии
US20190134004A1 (en) * 2016-06-16 2019-05-09 The University Of Chicago Methods and compositions for treating breast and prostate cancer
CN111356695B (zh) * 2017-10-27 2022-12-30 北京加科思新药研发有限公司 新的三环化合物
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent

Similar Documents

Publication Publication Date Title
AU2022340500A1 (en) Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma
JP2020519295A5 (cg-RX-API-DMAC7.html)
JP2016528162A5 (cg-RX-API-DMAC7.html)
JP2022542238A5 (cg-RX-API-DMAC7.html)
FI2547205T3 (fi) Uusia menetelmiä syövän kantasolujen kohdentamiseksi
JP2022506062A5 (cg-RX-API-DMAC7.html)
RU2018137037A (ru) Антинеопластические комбинации, содержащие hki-272 и винорелбин
JP2009215293A5 (cg-RX-API-DMAC7.html)
JP2023522716A5 (cg-RX-API-DMAC7.html)
JP2022501383A5 (cg-RX-API-DMAC7.html)
Jiang et al. Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts
JP2025061087A (ja) 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法
US20200397739A1 (en) Synergistic composition of vitamin c and vitamin k1, and compositions thereof for the treatment of cancer
JP2016502540A5 (cg-RX-API-DMAC7.html)
JP2016522188A5 (cg-RX-API-DMAC7.html)
JP6433686B2 (ja) 癌治療用組成物の調製のためのイカリチンの使用
WO2022207648A1 (en) A pi3k-delta inhibitor for the treatment of pancreatic cancer
JP2023550740A5 (cg-RX-API-DMAC7.html)
CN101757623B (zh) 一种5-ht受体激动剂固体药物组合物
CN104411309B (zh) 阿可拉定在制备用于治疗原发性肝癌的药物中的用途
JP2023549522A5 (cg-RX-API-DMAC7.html)
CN102370639A (zh) 一种萘普生和舒马普坦的复方制剂
JP7174370B2 (ja) 予後改善剤
Pramanik et al. Neutropenia due to palbociclib: A word of caution?
CN101155600A (zh) 放射线治疗增强剂